IL27RA and TMEM71, for instance, have been identified as subtype-specific immune markers in ILC and other breast cancer subtypes, potentially influencing metastatic tropism and treatment responsiveness.[22,23] These markers may help explain the distinct immunologic microenvironment observed in gastrointestinal metastases and point to potential avenues for immuno-targeted therapies. This evidence concerns the gene IL27RA and breast carcinoma.